Experts discuss latest results from EFFPAC and TINTIN trials presented at CIRSE 2019

Ulf Teichgräber (Jena, Germany) and Koen Deloose (Dendermonde, Belgium) discuss the 24-month results of the EFFPAC trial and the six-month outcomes of the TINTIN trial. Both trials used the luminor drug-coated balloon (DCB; iVascular) with TINTIN testing it in combination with the iVolution self-expanding stent (also iVascular). The latest trial results were presented at CIRSE 2019 (Cardiovascular and Interventional Radiological Society of Europe; 7–11 September; Barcelona, Spain).

Teichgräber, analysing the latest EFFPAC data, points out that luminor is a third-generation DCB with a “very innovative nanotechnology” that is designed to release paclitaxel just at the target lesion.

EFFPAC has shown “outstanding” results in terms of patency (90.2%) and freedom from TLR (97.2%) in the superficial femoral artery and popliteal artery for TASC A and B lesions, and at 24 months, no risk of increased death in the paclitaxel group, says Teichgräber.

The TINTIN trial is a physician-initiated trial evaluating the use of combined treatment with two products that have already “proven their efficacy”, says Deloose—the luminor DCB and the iVolution self-expanding stent—in complex and long lesions (mean lesion length of 24cm), such as those seen in real-world practice. At six months, TINTIN data “showed a clear and good signal” with a 96% primary patency and 98% freedom from target lesion revascularisation in patients with difficult disease, says Deloose.

This video is sponsored by iVascular.

Teichgräber, Ulf and Deloose, Koen

Add comment

Editor’s Peripheral Pick

    Subscribeto receive the very best in medical videos